阿尔茨海默氏症2030年:从精确基因组学到人工智能
Valeria D'Argenio1,2, Rossella Tomaiuolo3,4, Silvia Bargeri5
1Department of Human Sciences and Quality of Life Promotion, San Raffaele Open University, Via di Val Cannuta 247, 00166 Rome, Italy.
Genes
|February 27, 2026
概括
阿尔茨海默病 (AD) 风险受遗传学和性别的影响. 精准医学需要整合遗传数据,性别和性别因素,以制定有效的预防和治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 公共卫生 公共卫生
背景情况:
- 阿尔茨海默病 (AD) 构成了日益严重的全球健康挑战,预计患病率和成本将翻一番.
- 虽然生活方式因素很重要,但遗传学对晚期发病的阿尔茨海默病 (40-80%的遗传性) 有着显著的贡献.
- 性别和性别是关键的风险决定因素,由于生物和社会文化影响,妇女受到不成比例的影响.
研究的目的:
- 审查遗传和性别相关因素对阿尔茨海默病风险的影响.
- 探索全基因组关联研究 (GWAS) 和基因风险评分 (GRS) 在AD中精确基因组学的实用性.
- 检查人工智能 (AI) 和数字健康在个性化AD预防中的作用.
主要方法:
- 对大型全基因组关联研究 (GWASs) 的审查.
- 对精确基因组学的遗传风险评分 (GRS) 的分析.
- 在多式联网大数据分析中探索人工智能 (AI) 应用.
主要成果:
- 遗传因素对阿尔茨海默病的遗传性有很大影响.
- 全基因组关联研究 (GWAS) 正在推动遗传风险预测.
- 性别和性别显著调节AD风险,需要量身定制的方法.
结论:
- 对阿尔茨海默病的精准医学方法必须包含遗传,性别和性别信息.
- 整合人工智能和数字健康工具可以增强个性化的预防策略.
- 关于数据隐私的伦理考虑在开发新的AD干预措施时至关重要.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的疾病.在GWAS中,GWAS就是GWAS.人工智能的人工智能是人工智能.数据处理数据处理.数字健康数字健康伦理学 伦理 伦理学性别 性别 性别 性别 性别神经基因组学 神经基因组学更多相关视频
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.9K
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
19.5K
相关概念视频
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Pharmacogenomics: Identification of New Drug Targets
53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
